Bicara Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-68	-51.99	-37.85
Depreciation & Amortization	0.06	0.02	0.01
Asset Writedown & Restructuring Costs	-	0.57	-
Stock-Based Compensation	7.4	1.9	0.81
Other Operating Activities	-0.08	13.5	-
Change in Accounts Payable	2.64	-8.66	5.87
Change in Other Net Operating Assets	-16.77	-0.96	-0.92
Operating Cash Flow	-74.75	-45.63	-32.08
Capital Expenditures	-0.07	-0.59	-0.19
Sale of Property, Plant & Equipment	0.06	-	-
Investing Cash Flow	-0.01	-0.59	-0.19
Issuance of Common Stock	334.03	0.15	0.16
Financing Cash Flow	334.03	272.5	31.7
Net Cash Flow	259.27	226.28	-0.57
Free Cash Flow	-74.82	-46.21	-32.27
Free Cash Flow Per Share	-4.45	-79.66	-75.20
Cash Income Tax Paid	-	-	0
Levered Free Cash Flow	-53.72	-32.5	-
Unlevered Free Cash Flow	-53.72	-32.5	-
Change in Net Working Capital	9.61	8.9	-

Updated Mar 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q